Abstract
Bleeding oesophageal varices are a frequent and sometimes fatal complication of portal hypertension. Prompt resuscitation and arrest of haemorrhage are the immediate short term priorities. Vasoactive therapy to reduce portal pressure is administered on presentation. Early endoscopy is necessary to make a definitive diagnosis and initiate appropriate therapy; usually emergency sclerotherapy or banding. After the acute bleeding episode, follow-up therapy is instituted either to obliterate the varices by sclerotherapy or banding, or to chronically lower portal pressure and hence reduce the risk of bleeding pharmacologically; a combination of both strategies may be also used. Active surveillance of those at risk of developing varices is advocated. Long term β-blocker therapy has been demonstrated to be effective in both the primary prevention of variceal haemorrhage and the prevention of rebleeding in those who have already bled. Despite a multitude of therapeutic regimes and ongoing clinical trials, mortality from this condition remains disappointingly high.
Similar content being viewed by others
References
D’Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22(1): 332–54
Beppu K, Inokuchi K, Koyanagi N, et al. Prediction of variceal haemorrhage by esophageal endoscopy. Gastrointest Endosc 1981; 27: 213–8
North Italian Endoscopic club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1988; 319: 983–9
Bosch J, Groszman RJ, Garcia-Pagan J, et al. Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal haemorrhage: a placebo-controlled clinical trial. Hepatology 1989; 10(6): 962–8
Burroughs AK, Panagou E. Pharmacological therapy for portal hypertension: rationale and results. Semin Gastrointest Dis 1995; 6(3): 148–64
Levacher S, Letoumelin P, Pateron D, et al. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet 1995; 346: 865–8
Burroughs AK, McCormick PA, Hughes MD, et al. Randomized, double-blind, placebo-controlled trial of somatostatin for variceal rebleeding. Gastroenterology 1990; 99: 1388–95
Valenzuela JE, Schubert T, Fogel MR, et al. A multicenter, randomized, double-blind trial of somatostatin in the management of acute haemorrhage from esophageal varices. Hepatology 1989; 10(6): 958–61
Sung JJY, Chung SCS, Lai CW, et al. Octreotide infusion or emergency sclerotherapy for variceal haemorrhage. Lancet 1993; 342: 637–41
Jenkins SA, Shields M, Elias E, et al. A multicentre randomised trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage. Gut 1997; 41: 526–33
Besson I, Ingrand I, Person B, et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 1995; 333: 555–60
Avgerinos A, Nevens F, Raptis S, et al. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet 1997; 350: 1495–1500
Poison RJ, Westaby D, Gimson AES, et al. Sucralfate for the prevention of early rebleeding following injection sclerotherapy for esophageal varices. Hepatology 1989; 10(3): 279–82
Paquet KJ, Koussouris P, Keinath R, et al. A comparison of sucralfate with placebo in the treatment of esophageal ulcers following therapeutic endoscopic sclerotherapy of esophageal varices: a prospective controlled randomized trial. Am J Med 1991; 91: 147S–50S
Garg PK, Sidhu SS, Bhargava DK. Role of omeprazole in prevention and treatment of postendoscopic variceal sclerotherapy esophageal complications. Dig Dis Sci 1995; 40(7): 1569–74
Gimson A, Poison R, Westaby D, et al. Omeprazole in the management of intractable esophageal ulceration following injection sclerotherapy. Gastroenterology 1990; 99: 1829–31
Blaise M, Pateron D, Trinchet J, et al. Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1994; 20(1): 34–8
Bornman PC, Krige JEJ, Tereblanche J. Management of oesophageal varices. Lancet 1994; 343: 1079–83
Williams SGJ, Westaby D. Recent advances in the endoscopic management of variceal bleeding. Gut 1995; 36: 647–8
Lo GH, Lai KH, Cheng JS, et al. Emergency banding ligation versus sclerotherapy for the control of active bleeding from esophageal varices. Hepatology 1997; 25(5): 1101–4
Terblanche J, Bornman PC, Kahn D, et al. Failure of repeated injection sclerotherapy to improve long-term survival after oesophageal bleeding. Lancet 1983; 2: 1328–32
Gimson AES, Ramage JK, Panos MZ, et al. Randomised trial of variceal banding ligation versus injection sclerotherapy for bleeding oesophageal varices. Lancet 1993; 342: 391–4
Lo GH, Lai KH, Cheng JS, et al. A prospective, randomized trial of sclerotherapy versus ligation in the management of bleeding esophageal varices. Hepatology 1995; 22(2): 466–71
Lebrec D, Nouel O, Corbie M, et al. Propranolol-A medical treatment for portal hypertension. Lancet 1980; II: 180–2
Feu F, Garcia-Pagan JC, Bosch J, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal hemorrhage in patients with cirrhosis. Lancet 1995: 346: 1056–9
Poynard T, Cales P, Pasta L, et al. Beta-adrenergic antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. N Engl J Med 1991; 324(22): 1532–8
Reichen J. Liver function and pharmacological considerations in pathogenesis and treatment of portal hypertension. Hepatology 1990; 11(6): 1066–78
Elsayed SS, Shiha G, Hamid M, et al. Sclerotherapy versus sclerotherapy and propranolol in the prevention of rebleeding from oesophageal varices: a randomised study. Gut 1996; 38: 770–4
Hayes P, Davis JM, Lewis JA, et al. Meta-analysis of value of propranolol in prevention of variceal haemorrhage. Lancet 1990; 336: 153–6
Villaneuva C, Balanzo J, Novella MT, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996; 334(25): 1624–9
McCormick PA, Dick R, Burroughs AK. The transjugular portosystemic shunt (TIPS) in the treatment of portal hypertension. Aliment Pharmacol Ther 1994; 8(3): 273–82
McCormick PA, Dick R, Panagou EB, et al. Emergency transjugular intrahepatic stent shunting as salvage treatment for uncontrolled variceal bleeding. Br J Surg 1994; 81: 1324–7
McCormick PA, Kaye G, Greenslade L, et al. Esophageal staple transection as a salvage procedure after failure of acute injection sclerotherapy. Hepatology 1992; 5(3): 403–6
Greig JD, Garden OJ, Carter DC. Prophylactic treatment of patients with esophageal varices: is it ever indicated? World J Surg 1994; 18: 176–84
Veterans Affairs Cooperative Variceal Sclerotherapy Group. Prophylactic sclerotherapy for esophageal varices in men with alcoholic liver disease. N Engl J Med 1991; 324(25): 1779–84
Teran JC, Imperiale TF, Mullen KD, et al. Primary prophylaxis of variceal bleeding in cirrhosis: a cost-effectiveness analysis. Gastroenterology 1997; 112: 473–82
Perez-Ayuso RM, Pique JM, Bosch J, et al. Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet 1991; 337: 1431–4
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
McCormack, G., McCormick, P.A. A Practical Guide to the Management of Oesophageal Varices. Drugs 57, 327–335 (1999). https://doi.org/10.2165/00003495-199957030-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199957030-00005